Effects of garlic in treatment of pregnancy complications

The favorable effects of garlic on metabolic profiles, hs-CRP and biomarkers of oxidative stress in pregnant women at risk for pre-eclampsia

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT201312125623N15

Enrollment

Registered

2013-12-24

Start date

2013-12-02

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pregnancy. Sequelae of complication of pregnancy, childbirth and the puerperium

Interventions

Intervention 1: Intervention group: Garlic tablet, daily for 9 weeks. Intervention 2: Control group: Placebo tablet, daily for 9 weeks.

Treatment - Drugs

Intervention group: Garlic tablet, daily for 9 weeks

Control group: Placebo tablet, daily for 9 weeks

Eligibility

Sex/Gender

Female

Age

18 Years to 40 Years

Inclusion criteria

Inclusion criteria: Inclusion Criteria: Pregnant women; primigravida; aged 18-40 year old who were carrying singleton pregnancy at 27 weeks' gestation; positive roll-over test. Exclusion Criteria: Multiparous women; patients with hypertension; gestational diabetes mellitus (GDM); complete bed rest (CBR); intra uterine fetal death (IUFD); placenta abruption; preterm delivery.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Insulin. Timepoint: Baseline and End-of-trial. Method of measurement: Elisa.;Hs-CRP. Timepoint: Baseline and End-of-trial. Method of measurement: Elisa.;Total Antioxidant Capacity. Timepoint: Baseline and End-of-trial. Method of measurement: Spectrophotometry.;Total glutathione. Timepoint: Baseline and End-of-trial. Method of measurement: Spectrophotometry.;Fasting plasma glucose. Timepoint: Baseline and End-of-trial. Method of measurement: Spectrophotometry.	—

Measure

Time frame

Insulin. Timepoint: Baseline and End-of-trial. Method of measurement: Elisa.;Hs-CRP. Timepoint: Baseline and End-of-trial. Method of measurement: Elisa.;Total Antioxidant Capacity. Timepoint: Baseline and End-of-trial. Method of measurement: Spectrophotometry.;Total glutathione. Timepoint: Baseline and End-of-trial. Method of measurement: Spectrophotometry.;Fasting plasma glucose. Timepoint: Baseline and End-of-trial. Method of measurement: Spectrophotometry.

—

Countries

Iran (Islamic Republic of)

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026